IP Library Granted Patent US 8,642,577
Granted Patent B2
US 8,642,577 · App. 11/401,805 · Granted Feb 4, 2014

Compounds, compositions and methods for the treatment of poxvirus infections

Inventors: Merrick R. Almond (Apex, NC); George R. Painter (Chapel Hill, NC)
Assignee: Chimerix, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,577
App. No.
11/401,805
Granted
Feb 4, 2014
Kind
B2
Abstract

The present application provides methods and compositions for combination therapy with antiviral compounds for the treatment of poxvirus infections, such as orthopox virus infections. In one embodiment, a method of treatment of a poxvirus infection is provided that comprises administering to a host in need thereof cidofovir, cyclic cidofovir, or a salt, ester, or prodrug thereof in combination or alternation with at least a second anti-poxvirus agent. The second anti-poxvirus agent is, for example, a biologic, such as a pegylated interferon.

Claims (12)

1. A method for the treatment of a poxvirus infection comprising administering an effective amount of a prodrug of cidofovir having the structure:

or a pharmaceutically acceptable salt thereof, in combination or alternation with at least a second anti-pox virus agent to a host in need thereof, wherein the second anti-pox agent is Siga-246 (4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide), and the prodrug or a pharmaceutically acceptable salt thereof and the second anti-pox virus agent are each administered orally.

2. The method of claim 1 wherein the prodrug of cidofovir, or a pharmaceutically acceptable salt thereof and the second anti-pox virus agent are each administered in a pharmaceutically acceptable carrier.

3. The method of claim 1 wherein the prodrug of cidofovir, or a pharmaceutically acceptable salt thereof and the second anti-pox virus agent are administered in combination.

4. The method of claim 1 wherein the prodrug of cidofovir, or a pharmaceutically acceptable salt thereof and the second anti-pox virus agent are administered in alternation.

5. The method of claim 1 , wherein the poxvirus is an orthopox virus selected from the group consisting of variola major and minor, vaccinia, smallpox, cowpox, camelpox, mousepox, rabbitpox, and monkeypox.

6. The method of claim 1 , wherein the host is human.

7. The method of claim 1 , wherein the poxvirus is smallpox virus.

8. The method of claim 1 , wherein the poxvirus infection comprises more than one virus.

9. The method of claim 8 , wherein the at least one virus is an orthopoxvirus.

10. The method of claim 8 , wherein the at least one virus is selected from the group consisting of variola major and minor, vaccinia, smallpox, cowpox, camelpox, mousepox, rabbitpox, and monkeypox.

11. The method of claim 8 , wherein the at least one virus is vaccinia virus or cowpox virus.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 29, 2026
From: OHA AGENCY LLC, IN ITS CAPACITY AS ADMINISTRATIVE AGENT
To: EMERGENT BIODEFENSE OPERATIONS LANSING LLC
Reel/Frame 074509/0516 →
SECURITY INTEREST Recorded Apr 16, 2026
From: EMERGENT BIOSOLUTIONS INC.; EMERGENT BIODEFENSE OPERATIONS LANSING LLC; EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.; EMERGENT TRAVEL HEALTH INC.; EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 074389/0054 →
SECURITY INTEREST Recorded Sep 30, 2024
From: EMERGENT BIODEFENSE OPERATIONS LANSING LLC; EMERGENT BIOSOLUTIONS INC.; EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.; EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC; EMERGENT TRAVEL HEALTH INC.; EMERGENT BIOSOLUTIONS CANADA INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 068746/0698 →
WELLS FARGO BANK, NATIONAL ASSOCIATION Recorded Sep 3, 2024
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: EMERGENT BIODEFENSE OPERATIONS LANSING LLC
Reel/Frame 068828/0488 →
NOTICE OF GRANT OF SECURITY INTEREST IN U.S. PATENTS Recorded Sep 3, 2024
From: EMERGENT BIODEFENSE OPERATIONS LANSING LLC; EMERGENT BIOSOLUTIONS CANADA INC.; EMERGENT BIOSOLUTIONS INC.; EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC; EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.; EMERGENT TRAVEL HEALTH INC.
To: OHA AGENCY LLC
Reel/Frame 068828/0233 →
SECURITY INTEREST Recorded May 18, 2023
From: EMERGENT BIODEFENSE OPERATIONS LANSING LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 063689/0954 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE: EMERGENT BIODEFENSE OPERATIONS LANSING LLC 3500 MARTIN LUTHER KING JR. BLVD, LANSING, MICHIGAN 48906 PREVIOUSLY RECORDED AT REEL: 061720 FRAME: 0982. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 4, 2022
From: CHIMERIX, INC.
To: EMERGENT BIODEFENSE OPERATIONS LANSING LLC
Reel/Frame 062054/0526 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2022
From: CHIMERIX, INC.
To: EMERGENT BIODEFENSE OPERATIONS LANSING LLC
Reel/Frame 061720/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2006
From: ALMOND, MERRICK R.; PAINTER, GEORGE R.
To: CHIMERIX, INC.
Reel/Frame 018163/0459 →
Continuity (2)
Provisional Application 60669730 · Apr 8, 2005
Related Publication 20070003516A1 · Jan 4, 2007